Clinical Trial Search

Primary: Posttraumatic Stress Disorder (PTSD) Symptoms as Measured by the Clinician Administered Posttraumatic Stress Disorder Scale (CAPS) — 41.7; 43.3; 51.5 Scores on a scale

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 23; 21; 42; 69 Participants

Primary: Percent Heavy Drinking Days — 55.5; 65.1 percentage of days

Primary: Hemostasis at the Target Bleeding Site (TBS) at 6 Minutes Following Treatment Application. Hemostasis is Defined as no Detectable Bleeding at the TBS. — 99.2; 100 % of…

Primary: Oocytes — 19; 47 oocytes

Primary: Change in Adult ADHD Investigator Symptom Report Scale (AISRS) Score — -22.8 units on a scale

Primary: Change in Attention Deficit Hyperactivity Disorder Rating Scale-IV Parent Version Investigator-Scored (ADHD-IV-Parent: Inv) Total Score. — -20.1 units on a scale

Primary: Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 Weeks — 0.64; 0.44; 0.88; 0.88 proportion of participants

Primary: Number of Participants With Change in Sputum Markers by End of Study — 0; 0 Participants

Primary: Asthma Control Questionnaire (ACQ) — 1.15; 1.63; 1.39; 1.23 units on a scale

Primary: Median Percentage of CD4 Positive T-Cells — 62; 70; 58; 66 percentage positive T-cells

Primary: Incidence Rates of AIDS - Defining Illness, Serious Non-AIDS Defining, Cardiovascular, Renal, Hepatic Event, or Death — 0.21; 0.31 New cases per 100 person - years…

Primary: Reduction in Albuminuria — -5.5; -6.7 percentage of UACR change

Primary: Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6 — -0.99; -0.43 units on a scale — p=0.0140

Primary: Percent Change in Total Lesion Counts (TLs) From Baseline to Week 2 — -42.16; -35.33 Percent change in lesions — p=0.008